In a recent survey, about 70% of American adults expressed their concern over the use of artificial intelligence in healthcare, with the most concerned demographic being the Baby Boomers. This article delves into the details of the study, as well as an update on digital health companies, gene editing, and other related healthcare news.
Public sentiment towards AI in healthcare
A recent survey conducted by Morning Consult indicates a growing concern about the integration of artificial intelligence (AI) into healthcare among U.S adults. Approximately 70% of the respondents expressed their apprehensions, with artificial intelligence taking on roles in administrative tasks, surgical procedures, and other health-related operations. The findings also suggest that transparency from healthcare providers about AI involvement is a priority for many individuals.
Babylon's exit from the U.S market
Babylon, a digital health company that's been grappling with issues, has announced its decision to permanently shut down its Austin headquarters. Babylon has struggled to find a buyer in light of its mounting problems and has informed the Texas Workforce Commission of its intent to exit the U.S market. This decision brings about a wave of uncertainty for its employees and the patients under its care.
The promise and challenges of Crispr technology
The cutting-edge gene-editing technology, Crispr, holds significant potential in treating genetic disorders by modifying patients' DNA to rectify harmful mutations. Despite the immense promise, this technique does have certain drawbacks, as it introduces permanent changes. Companies like Amber Bio are working on targeting alterations to RNA, instead of DNA, to expand the scope of treatable genetic disorders and reduce associated safety risks.
Shares of Novo Nordisk experienced a surge this week following the release of clinical trial data that revealed their weight loss drug, Wegovy, reduced the risk of adverse cardiovascular events by 20%. This discovery is a significant development in the healthcare industry, potentially improving treatment options for patients struggling with weight-related health issues, particularly those with an elevated risk of cardiovascular complications.